TERT and neoplasm: The correct performance of clinical therapies relies greatly on the exact identification of the extent of the tumor as well as the accurate recognition of the main molecular biomarkers like the isocitrate dehydrogenase (IDH) mutation, 1p/19q co-deletion, and telomerase reverse transcriptase (TERT) promoter mutation [3].